Literature DB >> 15622485

Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents.

Tsunehiro Endo1, Masaharu Yoshikawa, Masaaki Ebara, Kazuki Kato, Masahiko Sunaga, Hiroyuki Fukuda, Akira Hayasaka, Fukuo Kondo, Nobuyuki Sugiura, Hiromitsu Saisho.   

Abstract

BACKGROUND: Metallothionein (MT), which is known to detoxify heavy metal ions, is considered to serve as a mechanism of resistance to platinum complex compounds. In the present study, MT expression in hepatocellular carcinoma (HCC) was immunohistologically investigated to clarify its relationship to clinical background factors and responsiveness to anticancer drugs.
METHODS: Specimens from 117 patients with HCC were immunohistologically studied, using a monoclonal anti-MT antibody. the percentage of MT-positive HCC (MT ratio) cells was determined, to evaluate the extent of staining with anti-MT antibody. Staining with an MT ratio of more than 50% was categorized as diffusely positive; an MT ratio of 5% to less than 50% was focally positive; and an MT ratio of less than 5% was negative. Twenty-two patients received repeated arterial infusion chemotherapy with carboplatin (CBDCA), a platinum-containing compound, and the MT expression was analyzed in relation to their chemotherapeutic response.
RESULTS: The ratio of MT-positive cells in HCC decreased with the degree of histological differentiation and also decreased with higher tumor stage. In patients treated with CBDCA, the ratio of MT-positive cells in responders was significantly lower than that in non-responders.
CONCLUSIONS: MT expression decreases with the degree of histological differentiation and decreases with increasing tumor stage in HCC. In addition, MT expression may lower the antitumor effect of CBDCA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15622485     DOI: 10.1007/s00535-004-1471-1

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  15 in total

1.  Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.

Authors:  William D Tap; Ke-Wei Gong; Judy Dering; Yiou Tseng; Charles Ginther; Giovanni Pauletti; John A Glaspy; Richard Essner; Gideon Bollag; Peter Hirth; Chao Zhang; Dennis J Slamon
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

2.  Comparative cisplatin reactivity towards human Zn7-metallothionein-2 and MTF-1 zinc fingers: potential implications in anticancer drug resistance.

Authors:  Anjala W Bulathge; Rhiza Lyne E Villones; Fabian C Herbert; Jeremiah J Gassensmith; Gabriele Meloni
Journal:  Metallomics       Date:  2022-09-15       Impact factor: 4.636

3.  Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis.

Authors:  Yoshiyuki Takahara; Mitsuo Takahashi; Hiroki Wagatsuma; Fumihiko Yokoya; Qing-Wei Zhang; Mutsuyo Yamaguchi; Hiroyuki Aburatani; Norifumi Kawada
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

4.  Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study.

Authors:  Julien Edeline; Jean-Luc Raoul; Elodie Vauleon; Anne Guillygomac'h; Karim Boudjema; Eveline Boucher
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

5.  Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade.

Authors:  Jharna Datta; Sarmila Majumder; Huban Kutay; Tasneem Motiwala; Wendy Frankel; Robert Costa; Hyuk C Cha; Ormond A MacDougald; Samson T Jacob; Kalpana Ghoshal
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

Review 6.  Metallothionein Lower Under-Expression in Benign Tumors than That in Malignant Tumors: Systematic Review Article and Meta-Analysis.

Authors:  Jie Zhang; Ruijie Sun; Yue Liu; Guinian Wang; Qinglu Wang
Journal:  Iran J Public Health       Date:  2014-06       Impact factor: 1.429

7.  Serum metallothioneins in childhood tumours-a potential prognostic marker.

Authors:  Jarmila Kruseova; David Hynek; Vojtech Adam; Rene Kizek; Richard Prusa; Jan Hrabeta; Tomas Eckschlager
Journal:  Int J Mol Sci       Date:  2013-06-06       Impact factor: 5.923

8.  Expression of Drug-Resistant Factor Genes in Hepatocellular Carcinoma Patients Undergoing Chemotherapy with Platinum Complex by Arterial Infusion.

Authors:  Tomoya Sakurada; Masaharu Yoshikawa; Masahiko Sunaga; Eriko Kobayashi; Nobunori Satoh; Osamu Yokosuka; Shiro Ueda
Journal:  Pharmaceutics       Date:  2010-09-09       Impact factor: 6.321

9.  Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular Carcinoma: Results of a Phase II Study.

Authors:  Aly M Azmy; Khalid E Nasr; Nagy S Gobran; M Yassin
Journal:  ISRN Oncol       Date:  2012-07-16

10.  Identification and characterization of MT-1X as a novel FHL3-binding partner.

Authors:  Xin Cai; Jinfeng Wang; Xin Huang; Wenliang Fu; Wenrong Xia; Minji Zou; Yuanyuan Wang; Jiaxi Wang; Donggang Xu
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.